2024 World Conference on Lung Cancer (WCLC) - Posters-P1.08B.02 Circulating T-Cell Immunosenescence in Patients with Unresectable Locally Advanced NSCLC: Preliminary Results of the SENLOAD Study

P1.08B.02 Circulating T-Cell Immunosenescence in Patients with Unresectable Locally Advanced NSCLC: Preliminary Results of the SENLOAD Study

Back to course

Pdf Summary

The SENLOAD study investigates T-cell immunosenescence in patients with unresectable locally advanced non-small cell lung cancer (LA NSCLC) undergoing standard treatment. The standard care for these patients involves concomitant platinum-based chemoradiotherapy (CTRT) followed by immune checkpoint blocker (ICB) consolidation. Immunosenescence markers like loss of CD28 and the expression of CD57 and KLRG1 have been linked to resistance against anti-PD-1/-L1 therapies, highlighting a need to assess their impact on LA NSCLC.<br /><br />In this preliminary study, variations in circulating T-cell immunosenescence were observed throughout the treatment course. 43% of the patients showed senescence in CD8 T-cells (T8sen) during ICB progression, potentially impacting treatment personalization. However, no direct relation to toxicity was noted.<br /><br />The study cohort comprised 60 participants, majorly male (63%), with a median age of 62 years. Adenocarcinoma was the most common histology (58.3%), and PD-L1 was expressed in 63% of tumors. Most patients (80%) received ICB, with durvalumab being the most common, although 20% could not proceed with ICB consolidation due to progression or contraindications. Toxicity was observed in 38% after CRT and 22% after ICB. The median progression-free survival (PFS) and overall survival (OS) were 23 and 27 months, respectively, with a 41.6% response rate post-CRT and a 75% disease control rate among those receiving ICB.<br /><br />The study highlighted that immunosenescence profiling, specifically the SIP (senescence-immunophenotype) status, could aid in personalizing treatment strategies for stage III-NSCLC. However, further analyses are required for a more comprehensive understanding.

Asset Subtitle

Jose Benítez

Meta Tag

Speaker Jose Benítez

Topic Local-Regional NSCLC

Keywords

T-cell immunosenescence

non-small cell lung cancer

platinum-based chemoradiotherapy

immune checkpoint blocker

CD8 T-cells

durvalumab

PD-L1 expression

progression-free survival

immunosenescence markers

treatment personalization